vs
Mativ Holdings, Inc.（MATV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Mativ Holdings, Inc.的1.7倍（$772.1M vs $463.1M），Mativ Holdings, Inc.净利率更高（21.8% vs 12.7%，领先9.0%），Revvity同比增速更快（5.9% vs 1.0%），Revvity自由现金流更多（$161.8M vs $8.0M），过去两年Revvity的营收复合增速更高（9.0% vs -3.8%）
Mativ Holdings是一家全球特种材料制造商，主要生产高性能先进聚合物、无纺布、过滤解决方案及功能性涂层材料，服务医疗、工业、消费品、航空航天、能源等领域，业务遍及北美、欧洲及亚太地区。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MATV vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$463.1M
营收增速更快
RVTY
高出4.9%
1.0%
净利率更高
MATV
高出9.0%
12.7%
自由现金流更多
RVTY
多$153.8M
$8.0M
两年增速更快
RVTY
近两年复合增速
-3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $463.1M | $772.1M |
| 净利润 | $100.8M | $98.4M |
| 毛利率 | 18.8% | — |
| 营业利润率 | 2.2% | 14.5% |
| 净利率 | 21.8% | 12.7% |
| 营收同比 | 1.0% | 5.9% |
| 净利润同比 | 6620.0% | 3.9% |
| 每股收益（稀释后） | $1.87 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MATVRVTY
| Q4 25 | $463.1M | $772.1M | ||
| Q3 25 | $513.7M | $698.9M | ||
| Q2 25 | $525.4M | $720.3M | ||
| Q1 25 | $484.8M | $664.8M | ||
| Q4 24 | $458.6M | $729.4M | ||
| Q3 24 | $498.5M | $684.0M | ||
| Q2 24 | $523.8M | $691.7M | ||
| Q1 24 | $500.2M | $649.9M |
净利润MATVRVTY
| Q4 25 | $100.8M | $98.4M | ||
| Q3 25 | $-3.2M | $46.7M | ||
| Q2 25 | $-9.5M | $53.9M | ||
| Q1 25 | $-425.5M | $42.2M | ||
| Q4 24 | $1.5M | $94.6M | ||
| Q3 24 | $-20.8M | $94.4M | ||
| Q2 24 | $-1.4M | $55.4M | ||
| Q1 24 | $-28.0M | $26.0M |
毛利率MATVRVTY
| Q4 25 | 18.8% | — | ||
| Q3 25 | 19.3% | 53.6% | ||
| Q2 25 | 19.7% | 54.5% | ||
| Q1 25 | 15.0% | 56.5% | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 18.8% | 56.3% | ||
| Q2 24 | 20.8% | 55.7% | ||
| Q1 24 | 16.8% | 54.6% |
营业利润率MATVRVTY
| Q4 25 | 2.2% | 14.5% | ||
| Q3 25 | 3.1% | 11.7% | ||
| Q2 25 | 3.8% | 12.6% | ||
| Q1 25 | -88.8% | 10.9% | ||
| Q4 24 | 0.6% | 16.3% | ||
| Q3 24 | 1.4% | 14.3% | ||
| Q2 24 | 2.0% | 12.4% | ||
| Q1 24 | -2.8% | 6.8% |
净利率MATVRVTY
| Q4 25 | 21.8% | 12.7% | ||
| Q3 25 | -0.6% | 6.7% | ||
| Q2 25 | -1.8% | 7.5% | ||
| Q1 25 | -87.8% | 6.4% | ||
| Q4 24 | 0.3% | 13.0% | ||
| Q3 24 | -4.2% | 13.8% | ||
| Q2 24 | -0.3% | 8.0% | ||
| Q1 24 | -5.6% | 4.0% |
每股收益（稀释后）MATVRVTY
| Q4 25 | $1.87 | $0.86 | ||
| Q3 25 | $-0.06 | $0.40 | ||
| Q2 25 | $-0.18 | $0.46 | ||
| Q1 25 | $-7.82 | $0.35 | ||
| Q4 24 | $0.03 | $0.77 | ||
| Q3 24 | $-0.38 | $0.77 | ||
| Q2 24 | $-0.03 | $0.45 | ||
| Q1 24 | $-0.52 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.2M | $919.9M |
| 总债务越低越好 | $1.0B | — |
| 股东权益账面价值 | $498.7M | $7.3B |
| 总资产 | $2.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 2.07× | — |
8季度趋势，按日历期对齐
现金及短期投资MATVRVTY
| Q4 25 | $84.2M | $919.9M | ||
| Q3 25 | $97.1M | $931.4M | ||
| Q2 25 | $95.6M | $991.8M | ||
| Q1 25 | $84.0M | $1.1B | ||
| Q4 24 | $94.3M | $1.2B | ||
| Q3 24 | $162.2M | $1.2B | ||
| Q2 24 | $133.4M | $2.0B | ||
| Q1 24 | $128.9M | $1.7B |
总债务MATVRVTY
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.2B | — | ||
| Q1 24 | $1.2B | — |
股东权益MATVRVTY
| Q4 25 | $498.7M | $7.3B | ||
| Q3 25 | $397.4M | $7.4B | ||
| Q2 25 | $416.6M | $7.6B | ||
| Q1 25 | $428.2M | $7.6B | ||
| Q4 24 | $858.5M | $7.7B | ||
| Q3 24 | $882.3M | $7.9B | ||
| Q2 24 | $898.0M | $7.9B | ||
| Q1 24 | $906.9M | $7.8B |
总资产MATVRVTY
| Q4 25 | $2.1B | $12.2B | ||
| Q3 25 | $2.0B | $12.1B | ||
| Q2 25 | $2.1B | $12.4B | ||
| Q1 25 | $2.1B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B | ||
| Q2 24 | $2.6B | $13.4B | ||
| Q1 24 | $2.7B | $13.4B |
负债/权益比MATVRVTY
| Q4 25 | 2.07× | — | ||
| Q3 25 | 2.63× | — | ||
| Q2 25 | 2.66× | — | ||
| Q1 25 | 2.67× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 1.32× | — | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | 1.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $8.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 1.7% | 21.0% |
| 资本支出强度资本支出/营收 | 2.4% | 2.6% |
| 现金转化率经营现金流/净利润 | 0.19× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $93.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MATVRVTY
| Q4 25 | $19.3M | $182.0M | ||
| Q3 25 | $72.8M | $138.5M | ||
| Q2 25 | $57.6M | $134.3M | ||
| Q1 25 | $-15.9M | $128.2M | ||
| Q4 24 | $24.1M | $174.2M | ||
| Q3 24 | $37.6M | $147.9M | ||
| Q2 24 | $46.1M | $158.6M | ||
| Q1 24 | $-13.0M | $147.6M |
自由现金流MATVRVTY
| Q4 25 | $8.0M | $161.8M | ||
| Q3 25 | $66.7M | $120.0M | ||
| Q2 25 | $48.9M | $115.5M | ||
| Q1 25 | $-29.8M | $112.2M | ||
| Q4 24 | $2.0M | $149.8M | ||
| Q3 24 | $25.5M | $125.6M | ||
| Q2 24 | $37.4M | $136.6M | ||
| Q1 24 | $-25.1M | $129.7M |
自由现金流率MATVRVTY
| Q4 25 | 1.7% | 21.0% | ||
| Q3 25 | 13.0% | 17.2% | ||
| Q2 25 | 9.3% | 16.0% | ||
| Q1 25 | -6.1% | 16.9% | ||
| Q4 24 | 0.4% | 20.5% | ||
| Q3 24 | 5.1% | 18.4% | ||
| Q2 24 | 7.1% | 19.7% | ||
| Q1 24 | -5.0% | 20.0% |
资本支出强度MATVRVTY
| Q4 25 | 2.4% | 2.6% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 2.9% | 2.4% | ||
| Q4 24 | 4.8% | 3.4% | ||
| Q3 24 | 2.4% | 3.3% | ||
| Q2 24 | 1.7% | 3.2% | ||
| Q1 24 | 2.4% | 2.7% |
现金转化率MATVRVTY
| Q4 25 | 0.19× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 16.07× | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MATV
| Other | $208.7M | 45% |
| SAS Segment | $157.4M | 34% |
| FAM Segment | $97.0M | 21% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
